阿尔茨海默病药物治疗进展  

Advances in therapeutic drugs for Alzheimer disease

作　　者：张力翔 肖卫忠[1,2] Zhang Lixiang;Xiao Weizhong(Department of General Medicine,Peking University Third Hospital,Beijing 100191,China;Department of Neurology,Peking University Third Hospital,Beijing 100191,China)

机构地区：[1]北京大学第三医院全科医学科,北京100191 [2]北京大学第三医院神经内科,北京100191

出　　处：《中华全科医师杂志》2025年第3期336-342,共7页Chinese Journal of General Practitioners

摘　　要：阿尔茨海默病是一种进展性神经退行性疾病,随着全球老龄化进程,其已成为一个重要的公共卫生问题,开发有效的治疗药物尤为迫切。该文综述了阿尔茨海默病药物治疗的新进展,包括淀粉样蛋白和tau蛋白相关的疾病修正药物以及一些传统药物和新型药物2、3期临床试验的结果等。近年来尽管相关药物研发取得了一定的进展,但多数新药在大规模临床试验中未显示出长期临床获益。此外,药物高昂的成本、严重的不良反应等为其的临床推广带来了不小的挑战。我们还需继续探索新的治疗靶点和策略,以期为阿尔茨海默病患者提供更好的治疗选择。Alzheimer disease is a progressive neurodegenerative disorder which has emerged as a major public health concern with the global population aging,and the development of effective therapeutic agents has become increasingly urgent due to its rapid increase in prevalence.There is some progress in drug development,however,the majority of new drugs have failed to demonstrate sustained clinical efficacy in large‑scale trials.In addition,high costs,severe side effects have further hindered the widespread application of these therapies.This article reviews recent progress in the development of pharmacological treatments for Alzheimer disease,focusing on disease‑modifying therapies targeting amyloid‑βand tau proteins,also analyzes the results of phase 2 and phase 3 clinical trials of traditional and novel drugs.Future research efforts should continue to explore novel therapeutic targets and strategies to offer more effective treatment options for patients with Alzheimer disease.

关 键 词：阿尔茨海默病 药物治疗 淀粉样蛋白 TAU蛋白质类 

分 类 号：R74[医药卫生—神经病学与精神病学]